The first seed will be planted in Jurata Thin Film, a revolutionary vaccine storage technology. Photo by dszc Getty Images

Planting a seed seems like a quaint activity, but the University of Texas at Austin doesn't do anything small. Its new $10 million UT seed fund is going into incubation soon, thanks to the efforts of Discovery to Impact, the team leading the University's "research commercialization and innovation efforts."

Except for its scale, this project is no different from any other seed investment, which inputs capital into a business in the form of a lump sum, in exchange for a portion of the business. In this case, the recipients are "promising new startups built on university-owned intellectual property," according to a press release. In total, UT Austin estimates that this intellectual property, or research enterprise, totals $800 million, a number it commits to "dramatically expand."

“By investing in these early-stage companies, we will be addressing a crucial gap in the capital market and enabling development of impactful technologies, while encouraging investors to consider opportunities coming out of the university,” said vice president of business strategies and operations Jim Davis in the release.

Discovery to Impact helps launch startups and stays on board through the many growing pains many startups experience, helping to accelerate "new products, services, solutions and cures." This means choosing and collaborating with three or four new companies each year, and when divided, the seed does appear rather small: companies can expect no more than a $250,000 investment.

The first seed will be planted in Jurata Thin Film, in order to grow solutions that streamline vaccine and biologic development and distribution worldwide. As many who followed COVID-19 vaccine news are aware, one major problem in distributing a vaccine is keeping it cold and stable. Jurata, based on the work of UT College of Pharmacy professor Maria Croyle, makes "thin films" (look up this keyword to see how unique Croyle's contribution is) that preserve vaccines for up to three years at room temperature. This is excellent news for communities with fewer resources or more arduous shipping needs.

The company is still relatively young, although not brand-new, having been founded in 2019. Its leadership has more experience; CEO Sheila Mikhail and co-founder Jude Samulski have previously collaborated on Asklepios BioPharmaceutical Inc. (AskBio) and Bamboo Therapeutics Inc.

The UT Seed Fund investment, along with other funding, will help bring about a pilot-scale manufacturing line that can create 1,000 doses of loaded thin films per hour, plus studies to ensure the safety of the formulation under the tongue, inside the cheek, and via intramuscular injection.

“Jurata is very excited to be the first recipient of UT Seed Fund,” said Jurata’s senior director of business development, Megan Livingston. “UT has been extremely supportive of our technology and development, and we look forward to continuing our relationship through this investment.”

A similar seed fund already exists at the University of Texas at Dallas, with larger sums for each business. More information about research at UT Austin is available at utexas.edu.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”